Alder BioPharmaceuticals to Host Conference Call to Discuss Second Quarter 2016 Financial and Operating Results
Alder BioPharmaceuticals, Inc. (ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will report its second quarter 2016 financial and operating results after the close of U.S. financial markets on Tuesday, July 26, 2016. Alder management will host a conference call and live audio webcast to discuss the results and provide a general business update at 5:00 p.m. ET the same day.
The live call may be accessed by dialing (877) 430-4657 for domestic callers or (484) 756-4339 for international callers, and providing conference ID number 29548578. A live webcast can be accessed from the Events & Presentations page of the Investors section on Alder’s website at http://www.alderbio.com. An archived replay of the event will be available on Alder’s website for 30 days after the live event concludes.
About Alder BioPharmaceuticals
Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. ALD403, Alder’s lead pivotal-stage product candidate being evaluated for migraine prevention, is a genetically engineered monoclonal antibody that inhibits calcitonin gene-related peptide. Alder’s second program, ALD1613, targets adrenocorticotropic hormone and is intended for the treatment of congenital adrenal hyperplasia and Cushing’s disease. Clazakizumab, Alder’s third program, is a monoclonal antibody candidate designed to block interleukin-6 and is licensed to Vitaeris, Inc. For more information, please visit http://www.alderbio.com.